Inclusion of the EXAMINE study in a meta-analysis of the addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia

The main eligibility criterion in Salvo and colleagues’ meta-analysis on the increased risk of hypoglycaemia was that trials studied the effect of adding one dipeptidyl peptidase-4 (DPP-4) inhibitor or placebo to sulphonylureas.1